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Background: Risk classification and prediction of prognosis in GIST is still a matter of debate. Data on the impact of
age and gender as potential confounding factors are limited. Therefore we comprehensively investigated age and
gender as independent risk factors for GIST.
Methods: Two independent patient cohorts (cohort I, n = 87 [<50 years]; cohort II, n = 125 [≥50 years]) were
extracted from the multicentre Ulmer GIST registry including a total of 659 GIST patients retrospectively collected in
18 collaborative German oncological centers. Based on demographic and clinicopathological parameters and a
median follow-up time of 4.3 years (range 0.56; 21.33) disease-specific-survival (DSS), disease-free-survival (DFS) and
overall survival (OS) were calculated.
Results: GIST patients older than fifty years showed significantly worse DSS compared to younger patients
(p = 0.021; HR = 0.307, 95% CI [0.113; 0.834]). DSS was significantly more favorable in younger female GIST patients
compared with elderly females (p = 0.008). Female gender resulted again in better prognosis in younger patients
(p = 0.033).
Conclusions: Patient age (<50 years) and female gender were significantly associated with a more favourable
prognosis in GIST. Extended studies are warranted to confirm our clinical results and to elucidate underlying
pathophysiological mechanisms.
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Based on the molecular pathogenesis of driver gain-of-
function mutations in c-kit (80-90%) [1-4] and less fre-
quently in the PDGFRα gene (5-10%), gastrointestinal
stromal tumors (GIST) became a molecular model
tumor in oncology emphasized by the central role of re-
ceptor tyrosine kinases in their molecular pathogenesis
and the availability of small molecule inhibitor therapy.
GIST occur with an annual incidence of 7 to 20 per
million [5-9]. Most patients with GIST are diagnosed
within the 7th decade [10,11]. Less than 10% of patients
with GIST are younger than forty. There are also some
single reports on pediatric GIST, which appear to be a
different disease entity [12-14]. Although large-scale* Correspondence: klaus.kramer@uniklinik-ulm.de
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unless otherwise stated.multi-centre studies are available (e.g. the population-
based study from Sweden [5], the Surveillance, Epidemi-
ology and End Results (SEER) database [10] and the
AFIP studies [15,16], data are limited on the impact of
age and gender related to risk classifications and/or pre-
diction of prognosis in GIST. In particular it is still un-
clear whether prognosis of GIST in adult patients may
be significantly altered by age (i.e. patients with an age
younger than 50 years) and/or gender-related factors.
Therefore, the aim of the present retrospective analysis
was to elucidate comprehensively clinicopathological
features of GIST patients younger than 50 years to iden-
tify potential age and gender-related effects on patient
outcome.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Schematic diagram for study populations.
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Data of the independent multicentre Ulmer GIST regis-
try were used to extract age-dependent patient cohorts
(under and above 50 years of age at diagnosis) for fur-
ther comparative analyses. Patient data of the multicen-
tre GIST registry were retrospectively obtained from 18
collaborative oncological centres in Southern-Germany
between 2004 and 2009. Substantial demographic and/or
social selection bias of patients could be excluded since
all contributing centres are part of general or university
hospitals. As previously outlined in detail [17], data
registration of the multicentre Ulmer GIST registry is
strictly based on clearly defined methodological criteria,
such as Strengthening of the Reporting of Observa-
tional Studies in Epidemiology (STROBE) Statement
and the User’s Guide to Registries Evaluating Patient
Outcomes [18-21].
Briefly, all patients from study centres with proven
diagnosis of GIST were consecutively included unless
they refused consent. The study was approved by the
Ethics Committee of the Medical Faculty of the Univer-
sity of Ulm (No. 90 + 91/2006). Diagnosis of GIST was
based on currently applied diagnostic criteria [16,22]
using histological characteristics (e.g. highly cellular
spindle/epithelioid/mixed cell tumors), immunohisto-
chemical status (positivity for KIT or PDGFRα) and mu-
tational analysis of relevant c-kit and PDGFRα exons.
Clinical data were retrospectively reviewed based on the
hospital records including medical history and clinical
follow-up. In addition, personal contact as well as tele-
phone interview and/or review of medical charts in case
of re-admission of patients served for data acquisition.
The following parameters were defined as the most rele-
vant clinical and clinicopathological features for the
present work: age, gender, tumor localization (stomach
vs. small intestine), histological subtype (spindle cell tu-
mors vs. epithelioid/mixed cell tumors), primary tumor
size (cut-off 1, 5 and 10 cm), mitotic rate (cut-off 5 and
10 per 50 HPF), immunohistochemical status of KIT or/
and PDGFRα (if uncertain: mutational status), secondary
malignancy (yes vs. no), risk classification according to
Fletcher et al. [23] (i.e. high vs. non-high) and according
to Miettinen et al. [15] (i.e. high vs. non-high), tumor re-
currence and/or metastasis.
At the time of data analysis for the present study, the
multicentre Ulmer GIST registry consisted of 659 GIST
patients (Figure 1). Since a previous clinical study by
Cao et al. [24] suggested an age of 50 years as significant
cut-off for the discrimination between GIST patients
with worse and good prognosis, we stratified patients
from our Ulmer GIST registry accordingly. 87 of the 659
GIST patients (13.2%) were younger than 50 years and
defined as sub-cohort I, “young”. To establish a control
cohort with an age of ≥50 years at time of diagnosis, allremaining 572 GIST patients of the Ulmer GIST registry
older than 50 years were defined as sub-cohort II+. To
ensure highest completeness of clinical and follow up
data, we extracted a sub-cohort from the sub-cohort II+
that included only those GIST patients that derived
from the oncology center at the University Hospital of
Ulm, finally encompassing a total of 125 GIST patients
(study cohort II, “old”). The overall median follow-up
time for both study groups, the sub-cohort I (“young”)
and sub-cohort II (“old”), was 4.3 years (range 0.56;
21.33).Statistical analyses
Two-sided χ2-test or Fisher’s exact test were applied, as
appropriate, to check for differences of the demographic,
clinical and clinicopathological parameters between the
independent study-cohorts. Estimates for disease-free-
survival (DFS), disease-specific-survival (DSS) and overall-
survival (OS) were obtained by the Kaplan-Meier method
and differences between Kaplan-Meier curves were inves-
tigated by the log-rank test. For analysis of DSS non
GIST-related deaths were censored.
To prove the most relevant findings of the Kaplan-Meier
analyses, an additional multivariate Cox proportional haz-
ards regression model has been established for DSS and
DFS. The variables gender, age, tumor localization have
been defined as the most relevant independent variables of
the model. If applicable, the Hazard Ratio (HR) and 95%
confidence interval (95% CI) were calculated regarding
tumor-related death and tumor recurrence and/or metas-
tasis by applying univariate Cox proportional hazards
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treatment of GIST patients with the tyrosine kinase inhibi-
tor imatinib, Kaplan-Meier analyses were recalculated, cen-
soring all end-points and follow-ups after initiating of
imatinib.
Statistical analysis was performed using SPSS V19.0
(SPSS Inc., USA). Level of significance was set to α = 0.05.
Since all results rely on testing retrospective data, inter-
pretation of hypotheses was done in an explorative man-
ner. Therefore an adjustment of the significance level due
to multiple testing has been not performed.
Results
Table 1 comprises all demographic and clinicopathologi-
cal data of GIST patients enrolled in sub-cohort I
(“young”, <50 years) and sub-cohort II (“old”, ≥50 years).
Whereas the gender ratio, the tumor localization and
histotypes, tumor size, mitotic rate, and risk scores ac-
cording to Fletcher et al. [23] and Miettinen et al. [15]
were similar between both subgroups, some parameters
differed age-dependently (Table 2). In patients older than
50 years small GIST tumors (<1 cm) (p = 0.002 (Fisher’s
exact), OR = 11.2, 95%CI: 1.5, 87.0) as well as secondary
malignancies were more frequent (p < 0.001 (χ2-Test),
OR = 3.5 95% CI: 1.6, 7.2) and more GIST-related deaths
occurred (p = 0.017 (Fisher’s exact), OR = 3.1, 95% CI:
1.1, 8.7). Syndromic diseases (Neurofibromatosis type 1,
Carney triad) were found in three and four patients of
sub-cohort I and II (both 3.4%), respectively.
Survival analysis
At date of diagnosis the rate of metastasis was not differ-
ent between sub-cohort I (10.3%) and sub-cohort II
(12.8%; p = 0.586, Table 1). The outcome of GIST pa-
tients was generally more favourable in young patients
(cohort I) vs. older patients (cohort II). DSS rates after
1-, 3- and 5-year follow-up in “young” vs. “old” patients
were 98.5% vs. 96.2%, 96.6% vs. 87.0% and 96.6% vs.
81.2%, respectively. After 5-year follow up DSS was sig-
nificantly better in GIST patients younger than 50 years
(p = 0.015, log-rank-test; Figure 2). A multivariate Cox
regression model adjusted for gender and tumor
localization confirmed improved outcome for younger
patients (p = 0.036, HR = 0.27, 95% CI: 0.079, 0.921).
Moreover, we elucidated whether age as a continuous
variable is an independent prognostic factor. Again we
could show that the older age was associated with an in-
creased risk for DSS (p = 0.002, HR = 1.049, 95% CI:
1.018, 1.080) and OS (p < 0.0001; HR = 1.051, 95% CI:
1.029, 1.074).
Next we investigated differences for DSS rates between
“young” and “old” GIST patients (sub-cohort I vs. II)
considering selected demographic and clinicopathologi-
cal parameters as well as different risk scores as given inTable 3 and Additional file 1: Table S1. Most strikingly a
more favourable DSS after 5 years was found in female
“young” patients (p = 0.008, log-rank-test, Figure 3A),
but not in men. Calculation of the corresponding HR
failed since only censored events were observed in sub-
cohort I. Moreover, DSS was better for “young” GIST
patients with high risk classification according to
Fletcher et al. [23] (p = 0.004;HR = 0.15, 95% CI: 0.04;
0.66), tumor size above 5 cm (p = 0.008; HR = 0.11, 95%
CI: 0.01; 0.81), a mitotic rate ≥5/50 HPF (p = 0.026;
HR = 0.22, 95% CI: 0.05; 0.95) and tumor localization in
the stomach (p = 0.036; HR = 0.15, 95% CI:0.02; 1.17) ac-
cording to univariate Cox regression models.
Additional analyses regarding DSS after 5 years in rela-
tionship to demographic and clinicopathological param-
eters as well as different risk scores in each sub-cohort
revealed a more favourable outcome in “young” female
patients (p = 0.033,log-rank test; Table 3 and Additional
file 1: Table S2, Figure 3B) whereas DSS was not gender-
specific different (p = 0.596) in sub-cohort II (“old").
Moreover DSS was improved in “young” patients with
non-high risk GIST (p = 0.027) and with tumors charac-
terized by a mitotic rate below 5/50 HPF (p = 0.038).
DSS was also significantly improved in “old” patients
with non-high risk GIST (p < 0.001, HR = 0.09, 95% CI:
0.03; 0.31), in GIST with mitotic rate <10/50HPF (p <
0.001, HR = 0.15, 95% CI: 0.06; 0.39) and with tumors
sized <5 cm (p = 0.012, HR = 0.23, 95% CI: 0.07; 0.81).
DFS-rates for the follow-up times of 1-, 3-, and 5-
years were 88.4%, 81.2% and 78.8% in sub-cohort I as
compared to 79.0%, 74.2% and 69.6% in sub-cohort II
(Table 1), indicating no significant differences (p = 0.364,
log-rank-test; p = 0.916, multivariate Cox model adjusted
for gender and tumor localization; HR = 0.968, 95% CI:
0.534, 1.756). Regarding tumor size ≥10 cm (p = 0.014,
HR = 0.36, 95% CI: 0.14;0.90), mitotic rate ≥10/50 HPF
(p = 0.011; HR = 0.34, 95% CI: 0.12; 0.92) and high-risk
classification (p = 0.011; HR = 0.44, 95% CI: 0.22; 0.89)
DFS was more favourable in “young” GIST patients (de-
tailed data regarding log-rank test and OR at five years
see Additional file 1: Table S3).
OS-rates were compared after 1-, 3- and 5-year follow
up between sub-cohort I (98.5%, 93.2% and 91.2%) and
sub-cohort II (90.8%, 77.4% and 67.0%, Table 1). Again
GIST patients younger than 50 years showed a more
favourable outcome which was significantly different
(p <0.001; HR = 0.292, 95% CI: 0.140; 0.606, Figure 4A).
Regarding gender aspects again female patients particu-
larly with an age <50 years showed better OS (p = 0.002,
log-rank test; p = 0.008, cox model; HR = 0.141, 95% CI:
0.033; 0.604, Figure 4B).
To replicate the association of clinical outcome data
regarding age and gender we used study cohort II+
which included 572 GIST patients of the Ulmer GIST
Table 1 Demographic and clinical data of GIST patients of sub-cohort I (<50 years, “young”) and sub-cohort II
(≥50 years, “old”)
Parameter Sub-cohort I (n = 87) Sub-cohort II (n = 125)
<50 yr (“young”) ≥50 yr (“old”)
Age
median (range, yr) 41.7 (14.9;49.9) 68.2 (50.9; 94.1)
Sex n % n %
female 48 55.2 68 54.4
male 39 44.8 57 45.6
Localization
stomach 43 50.6 79 64.2
small intestine 29 34.1 35 28.5
colorectum 5 5.9 2 1.6
esophagus 1 1.2 1 0.8
EGIST 3 3.5 3 2.4
n.d. 4 4.7 3 2.4
Tumor size
median (range, cm) 5.5 (1.2; 27.0) 4.5 (0.4;40.0)
Risk according to Fletcher et al. [23] n % n %
high 29 41.4 35 31.8
intermediate 15 21.4 25 22.7
low 17 24.3 31 28.2
very Low 9 12.9 19 17.3
Risk according to Miettinen et al. [11]
high 22 33.3 30 29.7
intermediate 10 15.2 7 6.9
low 25 37.9 43 42.6
very Low 9 13.6 21 20.8
Histological subtype
spindle cell 63 85.1 98 89.1
Epithelioid/mixed 11 14.9 12 10.9
Immunohistochemistry
KIT pos 74 94.9 115 98.3
KIT neg 4 5.1 2 1.7
CD34 pos 48 82.8 84 84.0
CD34 neg 10 17.2 16 16.0
S100 pos 11 25.6 1 1.4
S100 neg 32 74.4 68 98.6
Clinical data
Metastasis atdiagnosis 9 10.3 16 12.8
Secondneoplasia 11 15.5 45 38.8
R0resection 81 93.1 112 89.6
Tumor debulking 4 4.6 7 7.2
Imatinib use 24 27.6 27 21.6
Recurrenceof disease and/ormetastasis
yes 21 25.9 32 29.6
Follow up time
mean (yr, ±SD) 4.90 (3.39) 5.65 (4.55)
median (range, yr) 4.28 (0.59;16.31) 4.57 (0.56;21.33)
deceased 9 10.3 40 32.0
alive 78 89.7 85 68.0
tumor-relateddeath 5 5.7 20 16.0
Survival rate % (n) % (n)
DSS (yr1/yr3/yr5) 98.5 (64)/96.6 (49)/96.6 (34) 96.2 (93)/87.0 (67)/81.2 (44)
DFS (yr1/yr3/yr5) 88.4 (57)/81.2 (41)/78.8 (29) 79.0 (74)/74.2 (55)/69.9 (36)
OS (yr1/yr3/yr5) 98.5 (64)/93.2 (49)/91.2 (34) 90.8 (93)/77.4 (67)/67.0 (44)
Syndromal disease 3xNF1 3.4% 3x NF1 2.4%
1x Carney 1%
yr, year; n.d., not defined; SD, standard deviation; DSS, disease specific survival; DSF, disease free survival; OS, overall survival; NF1, neurofibromatosis type 1;
Carney, Carney triad (coexistence of GIST, paraganglioma and pulmonal chondroma).
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Table 2 Comparsion of demographic and clinicopathological
parameters in sub-cohort I (“young”, n = 87) versus
sub-cohort II (“old”, n = 125)
Parameters n p-value*
age at diagnosis <50 yr vs. >50 yr 212 <0.001
Sex male vs. female 212 0.912
Tumor localization stomach vs. small intestine 187 0.210
GIST histotype spindle vs. epitheliod/
mixed
184 0.426
Tumor size <1 cm vs. ≥1 cm 199 0.002
<5 cm vs. ≥5 cm 199 0.524
<10 cm vs. ≥10 cm 199 0.605
Mitotic rate <5 vs. ≥5 / HPF 174 0.902
<10 vs. ≥10 / HPF 173 0.982
Risk acc.to Fletcher et al. high vs. non-high 180 0.189
Risk acc. to Miettinen et al. high vs. non-high 167 0.620
R0resection yes vs. no 193 0.321
TKI use (imatinib) yes vs. no 212 0.316
Secondary malignancies yes vs. no 187 <0.001
Cancer related death yes vs. no 212 0.017
yr, year; HPF, high power field; TKI, tyrosine kinase inhibitor;
*Two-sided χ2-test or Fisher’s exact test were applied as appropriate to check
for differences between both study-cohorts.
Figure 2 Kaplan–Meier curves of disease-specific survival (DSS) for GI
versus study cohort II (≥50 years at diagnosis, n = 125).
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and clinical data if provided for cohort II+ (Additional
file 1: Table S4) were not different compared to cohort
II “old” (Table 1). However, the median follow-up time
of cohort II+ was 3.25 years (range 0.01; 21.33) and ap-
proximately one year shorter compared with cohort II
(4.57 years, range 0.56; 21.33). As shown by Figure 5
more favourable outcome was found again for young
female GIST patients (<50 years) comparing DSS-rates
after a 5 year follow-up (p = 0.032, log-rank test).Discussion
The frequencies of GIST in men (54%) and women
(46%) [6] are quite similar. About three quarters of GIST
are diagnosed in patients aged above 50 years (median
58 years [25]). In population based series including cases
diagnosed at autopsy, the median age was approximately
ten years older (66 to 69 years) [5,7]. Combined data on
age and gender related to clinicopathological findings of
GIST and/or prognosis are limited. This may be of im-
portance since gender-related effects (e.g. hormonal sta-
tus) in younger GIST patients may contribute to GIST
prognosis.ST patients of study cohort I (<50 years at diagnosis, n = 87)
Table 3 Disease-specific survival (DSS) for GIST patients <50 years (sub-cohort I, “young”) versus ≥50 years (sub-cohort
II, “old”) related to GIST relevant clinicopathological parameters
Parameter Disease-specific survival (DSS) rates p-value1
Sub-cohort I (“young”) Sub-cohort II (“old”)
n = 87 n = 125
1 yr 3 yr 5 yr 1 yr 3 yr 5 yr
Sex male 96.9% 92,3% 92,3% 97,8% 84,8% 78,5% 0.326
female 100% 100% 100% 94,7% 88,6% 83,2% 0.008
p-value2 0.033 0.596
Localization Gaster 97,2% 97,2% 97,2% 97,0% 88,0% 83,4% 0.036
Small intestine 100% 93,8% 93,8% 96,4% 88,5% 78,6% 0.267
p-value2 0.225 0.813
Histotype Spindle 100% 97,4% 97,4% 96,4% 90,8% 83,5% 0.028
epitheliod/mixed 100% 100% 100% 91,7% 66,7% 66,7% 0.061
p-value2 0.695 0.097
Size <1 cm - - - 100,0% 100,0% 85,7% -
≥1 cm 100% 97,9% 97,9% 96,6% 87,5% 82,6% 0.012
p-value2 - 0.499
Size <5 cm 96,8% 92,2% 92,2% 100,0% 94,5% 90,9% 0.630
≥5 cm 100% 100% 100% 94,1% 83,8% 76,3% 0.008
p-value2 0.462 0.012
Size <10 cm 97,9% 95,0% 95,0% 98,6% 95,3% 93,1% 0.839
≥10 cm 100% 100% 100% 92,0% 71,1% 56,0% 0.010
p-value2 0.759 <0.001
Mitotic rate <5 / 50 HPF 100% 100% 100% 98,4% 96,2% 90,4% 0.131
≥5 / 50 HPF 100% 100% 100% 91,6% 73,7% 66,7% 0.026
p-value2 0.038 0.001
Mitotic rate <10 / 50 HPF 100% 100% 100% 97,4% 92,4% 88,2% 0.043
≥10 / 50 HPF 100% 100% 100% 89,7% 68,6% 56,1% 0.025
p-value2 <0.001 <0.001
Risk (NIH) high 100% 100% 100% 87,9% 68,4% 60,8% 0.004
non-high 100% 100% 100% 100,0% 98,0% 92,9% 0.227
p-value 0.027 <0.001
Risk (AFIP) high 100% 100% 100% 89,4% 70,5% 61,7% 0.018
non-high 100% 100% 100% 98,5% 94,4% 89,4% 0.084
p-value 0.013 <0.001
1Unadjustedp-values comparing data from study-cohort I vs. II considering DSS after 5 year follow-up.
2Unadjusted p-values comparing data within study-cohort I and II considering DSS rates after 5 year follow-up.
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comprehensively clinicopathological features of GIST and
patient outcome to elucidate more deeply the role of pa-
tient’s age and gender on the prognosis of GIST. We ana-
lyzed 87 GIST patients younger than fifty years (sub-
cohort I) and compared these study cohort with data from
a single-center collective of patients older than 50 years
(n = 125, sub-cohort II). Both collectives are part of the
multicentre Ulmer GIST registry, encompassing a total of
659 GIST patients at the time of study evaluation.First, our data demonstrate that generally the distri-
bution of gender, tumor localization, histotype, KIT
status, mitotic rate, median tumor size and risk classifi-
cation by different risk scores are similar between
patients younger or older than 50 years at time of diag-
nosis, in concordance with data of large series of GIST
patients [10,15]. More detailed analyses however re-
vealed a significant higher occurrence of small sized
GIST (<1 cm) in patients ≥50 years (sub-cohort II,
p = 0.002, OR = 11.2, 95%CI: 1.5; 87.0, Table 2). This
Figure 3 Age and gender related outcome regarding DSS. (A) Kaplan–Meier curves of disease-specific survival (DSS) for female GIST patients
of study cohort I (<50 years at diagnosis) versus study cohort II (≥50 years at diagnosis). (B) Kaplan–Meier curves of disease-specific survival (DSS)
for gender-related differences of GIST patients younger than 50 years at diagnosis (study cohort I).
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doscopies, radiological scans etc.) as well as surgical
procedures are more frequently performed in this age
group with a higher frequency of GIST diagnoses as an
incidental finding. Autopsy data also support thisFigure 4 Age and gender related outcome regarding OS. (A) Kaplan–M
(<50 years at diagnosis) versus study cohort II (≥50 years at diagnosis). (B) K
study cohort I (<50 years at diagnosis) versus study cohort II (≥50 years at dassumption indicating that 10 to 35% of histologically
investigated stomach tissues contain GIST-tumorlets
(micro-GIST [26-28]. As expected, elderly patients
(sub-cohort II) showed a significantly higher percentage
of secondary malignancies (38.8% vs. 15,5%, p < 0.001,eier curves of overall survival (OS) for GIST patients of study cohort I
aplan–Meier curves of overall survival (OS) for female GIST patients of
iagnosis).
Figure 5 Summary of unadjusted p-values for disease-specific
survival (DSS) of male and female GIST patients of study cohort
I (<50 years at diagnosis, n = 87) versus study cohort II+
(≥50 years at diagnosis, n = 572) after 5 year follow-up.
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ondary neoplasia in both GIST cohorts (sub-cohort I
plus II) with 29.9% are comparable to published data,
reporting secondary malignancies between 14% and
42% of GIST patients [29-31].
The first most striking result of our study is a significantly
more favorable DSS rate after 5 year follow up for patients
younger than 50 years in comparison to older patients (p =
0.015, log-rank-test; Figure 2) although patients ≥50 years
showed significantly more often smaller tumors (<1 cm).
The beneficial prognostic effect held true for OS (p < 0.001,
log-rank-test; Figure 4B) in younger patients but was not
seen regarding DFS (p = 0.364). Our data are supported by
Tran et al. [6] who reported that older age (>65 years) was
an independent predictor of mortality (OS) in GIST pa-
tients. In contrast a study including 188 patients showed
that younger age (<50 yrs) was associated with worse prog-
nosis in GIST (p = 0.035), highlighting a putative beneficial
prognostic value of older age in GIST [24]. Reasons for this
discrepancy may be due to the limited number of patients
in the study by Cao et al. as well as the clinical endpoint OS
used by the authors. Since, about 50% of death in GIST pa-
tients are not GIST-related, supported by our data, DSS
may be a more appropriate clinical endpoint in GIST for
outcome analyses.The second interesting result of our study was a gender-
related difference in patient outcome. Only younger
women showed better DSS (p = 0.008, Figure 3A) and this
effect held true after comparison of young female vs. male
GIST patients in cohort I (p = 0.033, Figure 3B). To ex-
clude confounding by the use of the tyrosine kinase in-
hibitor Imatinib, Kaplan-Meier analyses for DSS were
recalculated by censoring all patients who received TKI
treatment, resulting again in a more favourable prognosis
of young females (p = 0.047). These results are in accord-
ance with data from Miettinen et al. who reported an ex-
cellent long-term-prognosis particularly in female patients
younger than 21 years and gastric GIST [13]. In addition,
male gender was associated by some authors with a more
worse outcome [32,33].
The underlying mechanism for the gender-related more
favorable prognosis of GIST in patients younger than
<50 years remains unclear. There may be a relationship to
the reproductive age in younger females or to the use of
contraceptive medication but this is speculative and sev-
eral confounding factors need to be considered.
Young females are significantly overrepresented among
gastric GIST patients aged <40 years (>80%) [34-38].
Current knowledge confirms that the majority of GIST
in young adults as well as in children, particularly fe-
male patients, representing a distinctive disease entity
different from the kinase mutated GIST in adults
(so-called type 1 GIST). This subtype of GIST harbors
molecular alterations in the mitochondrial enzymatic
cascade succinate dehydrogenase (SDH). Mutations in
any of the four SDH subunits (A,B,C,D), either germ-
line or somatic, result in complete loss of the nuclear
expression of the subunit B shown by results of im-
munohistochemistry (SDHB-deficient or type 2 GIST)
[34-41]. Patients with germline mutations in SDHB
may develop both GIST and paraganglioma (= Carney-
Stratakis syndrome) [42]. On the other hand, patients
with the non-hereditary Carney triad (GIST, pulmonary
chondroma and paraganglioma) lack mutations in
the SDH complex. Instead, epigenetic silencing of the
SDH subunit C by DNA methylation as a novel non-
heritable mechanism for the development of Carney triad-
associated GIST may be more important [43]. Common to
the heterogeneous type 2 GISTs are the early age of onset
of disease before 40 years and a striking female predi-
lection of >80% except SDH subunit A mutated cases
which occur at relatively higher age and affect both
genders. Thus, regarding the prognostic impact of age
and gender, some of the young females of our study
cohort might have had type 2 GIST. Nevertheless,
given the low prevalence of SDHB-deficient GIST of
about 7% among gastric GIST [36], it appears to be un-
likely that a predominance of type 2 GIST may explain
entirely the age group effect of our study.
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In summary, we present first data on the prognostic
impact of age and gender in patients with GIST. The
favourable outcome in the young age group which is
gender-specific remains currently poorly understood.
The real impact of age- and gender-related biological
and pathophysiological factors on the prognosis in
GIST warrants further prospective studies on larger co-
horts with matched genotype and tumor site.
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